H.R. 9421: To prohibit a REMS-certified provider from prescribing mifepristone without an in-person visit and a medical license in the State in which the patient resides, and for other purposes.
H.R. 9421 status: Referred.
What this bill does
Overall score
Bill summary
AI SummaryThis bill would mandate in-person requirements for medication abortion nationwide, fundamentally restructuring access to reproductive healthcare and telehealth delivery models.
Key analysis
Impact analysis
Environment
Benefits
- No direct environmental impact identified.
Risks
- No direct environmental impact identified.
Economy
Benefits
- Standardizes in-person regulatory oversight for certain medical procedures.
Risks
- Increases administrative and compliance costs for telehealth providers.
- Disrupts existing supply chain and pharmacy delivery business models.
Society
Benefits
- Ensures in-person physician monitoring for specific medical interventions.
Risks
- Significantly restricts access to reproductive healthcare for rural or low-income populations.
- Creates potential legal and logistical barriers to medical privacy and telehealth equity.
How trustworthy & consequential it is
Confidence
highhigh
Information is complete and verified.
Analysis status
Full bill text (Congress.gov)
Source used for this bill's analysis.
Implementation risks causing significant disruption to established reproductive telehealth services nationwide.
Legal challenges regarding federal preemption of state telehealth laws are not fully addressed.
Where it stands
Introduced
CompleteCommittee
CurrentReferred
Floor
UpcomingEnacted
UpcomingHow it affects your district
Set your location
Add your district to see how this bill may affect your community and who to contact.
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.